Trial
NCT04933695
A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Amgen
Collaborators
—
Condition
Non-small Cell Lung Cancer
Intervention
Sotorasib
Why stopped
Futility
Provenance
Dataset: 2026-07-17 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-13